Dr. Jonathan Schoeff

speaker

2,131 appearances 2 recordings 1 series first heard Jul 2026 last heard 28 Jul

Dr. Jonathan Schoeff’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 2 in all, peaking in Jul 2026 with 2.

Appearances

newest first · ▶ plays the moment

Habits and Hustle · Episode 573: Dr. Jonathan Schoeff: Peptides and the Marketing Behind Modern Longevity - Part 1 · 21 Jul 2026 podcast

And GLP-1s do one thing and one thing only.

They improve insulin sensitivity, okay?

Now, how they achieve that can be through reduction in food noise, very powerful.

slowing of stomach emptying okay what we call delayed gastric emptying but those agents also work preferentially on the pancreas so they're improving insulin sensitivity so this goes to my point people want to say oh my gosh ozempic reduces the risk of heart attack yeah the the data said 20 reduction major adverse cardiac events

but it doesn't reduce the risk of heart disease.

It reverses insulin resistance.

Insulin resistance is the driver between heart disease and stroke.

So you can logically say, this is what I would expect to see.

Correct.

That is true.

Move to Europe?

I don't know.

Yeah.

Right?

Okay, I'd do that.

So, yeah, insulin resistance, understanding insulin resistance, the how, the why, the mechanistic nature of it, I think is really important because this is where all these groups come from, the carnivores, the ketos, all these things.

There is no one way.

Well, I mean, I think the fundamental argument is that GLP-1s are drugs.

Let's clear this up, okay?

GLP-1 in situ, produced by the human body, is a peptide, short-chain amino acid.

Showing 1441–1460 of 2,131 · page 73 of 107